Overview

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Status:
Terminated

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Rimonabant